微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 46.61% | -21.84% | -2.1% | 83/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 47.61% | -21.69% | -4.04% | 79/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 49.61% | -22.75% | -16.27% | 77/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 59.26% | 1.28% | -0.64% | 52/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 59.64% | 2.99% | -1.91% | 53/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 60.8% | 1.86% | -5.33% | 50/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 64.22% | 3.73% | 9.77% | 39/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 58.51% | 1% | 1.04% | 52/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 57.91% | -3% | -2.99% | 60/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 59.69% | -3.15% | -3.58% | 54/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 61.91% | 8.95% | 6.87% | 46/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 57.93% | 0.56% | -2.96% | 61/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 59.7% | 1.66% | -3.14% | 56/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 61.63% | 8.7% | 8.47% | 53/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 56.82% | -1.44% | -1.36% | 62/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 57.61% | 11.79% | -1.89% | 64/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 58.72% | 9.51% | 3.56% | 59/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 56.7% | 5.96% | -1.65% | 67/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 57.65% | -0.47% | 11.88% | 62/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 51.53% | -8.09% | -3.89% | 80/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 53.62% | -5.43% | 0.2% | 67/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 53.51% | -7% | -7.62% | 72/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 57.92% | -3.7% | 3.31% | 56/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 56.07% | 3.02% | -1.11% | 66/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 56.69% | 8.87% | -1.46% | 57/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 57.54% | 5.4% | -4.34% | 55/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 60.15% | 5.98% | 10.52% | 45/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 54.42% | 1.84% | 4.51% | 68/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 52.07% | -4.95% | -4.61% | 58/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 54.59% | -3.83% | -3.82% | 57/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 56.76% | -6.81% | 6.21% | 48/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 53.44% | 12.27% | -2.46% | 66/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 54.79% | 16.74% | -3.48% | 51/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 56.76% | 22.07% | -6.8% | 49/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 60.91% | 16.29% | 27.97% | 38/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 47.6% | 2.78% | 1.41% | 69/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 46.93% | 8.85% | 0.93% | 50/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 46.5% | 11.65% | -11.22% | 51/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 52.37% | 13.44% | 13.11% | 34/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 46.31% | 8.54% | 7.4% | 55/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 43.12% | -1.71% | 3.52% | 40/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 41.65% | -6.07% | -9.79% | 47/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 46.17% | -13.04% | 8.22% | 28/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |